Brief: Sangamo Therapeutics Announces U.S. FDA Clearance Of IND Application For ST-503
19/11/2024 22:14
Nov 19 (Reuters) - Sangamo Therapeutics Inc SGMO.O :
* SANGAMO THERAPEUTICS ANNOUNCES U.S. FDA CLEARANCE OF IND
APPLICATION FOR ST-503 FOR THE TREATMENT OF IDIOPATHIC SMALL
FIBER NEUROPATHY, A TYPE OF CHRONIC NEUROPATHIC PAIN
* SANGAMO THERAPEUTICS INC - TO INITIATE PHASE 1/2 STUDY FOR
ST-503 IN MID-2025
Source text: ID:nBwkJmPza
Further company coverage: SGMO.O